Management of fatigue in patients with multiple sclerosis

Drugs

Volumn 64, Issue 12, 2004, Pages 1295-1304

  Zifko, Udo A ^a,b  

^a Sonderkrankenanstalt Neurol K   (Austria)

^b Klinik Pirawarth   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; AMANTADINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; HYPNOTIC AGENT; IMMUNOMODULATING AGENT; METHYLTESTOSTERONE; MODAFINIL; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; PEMOLINE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT;

ABDOMINAL PAIN; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; ASPIRATION PNEUMONIA; BRAIN INJURY; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DAILY LIFE ACTIVITY; DEHYDRATION; DEPRESSION; DIZZINESS; EATON LAMBERT SYNDROME; ELECTROLYTE DISTURBANCE; ELECTROMAGNETIC FIELD; EXERCISE; FIBROMYALGIA; HEADACHE; HEART FAILURE; HEART PALPITATION; HEPATITIS; HUMAN; HYPOTHYROIDISM; INSOMNIA; LIVEDO RETICULARIS; LIVER DYSFUNCTION; MULTIPLE SCLEROSIS; MUSCLE CRAMP; MYOTONIC DYSTROPHY; NARCOLEPSY; NAUSEA; NERVOUSNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PARESTHESIA; PARKINSON DISEASE; PHYSICAL STRESS; QUALITY OF LIFE; RESTLESSNESS; REVIEW; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDER; TACHYCARDIA; THIRST; TREMOR; UNCONSCIOUSNESS; URINARY TRACT INFECTION; URINE RETENTION; VERTIGO; VISUAL ANALOG SCALE; VISUAL DISORDER; VISUAL HALLUCINATION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

AMANTADINE; ANTIDEPRESSIVE AGENTS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS; DOPAMINE AGENTS; ELECTROMAGNETIC FIELDS; EXERCISE; FATIGUE; HUMANS; MULTIPLE SCLEROSIS;

EID: 3142734448     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464120-00003     Document Type: Review

References (51)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1227-31
2. Zifko UA. Therapie der Tagesmüdigkeit bei Patienten mit Multipler Sklerose. Wien Med Wochenschr 2003; 153: 65-72
3. Comi G, Leocani L, Rossi P, et al. Physiopathology and treatment of fatigue in multiple sclerosis. J Neurol 2001; 248: 174-9
4. Djaidetti R, Ziv I, Achiron A, et al. Fatigue in multiple sclerosis compared with chronic fatigue syndrome: a quantitative assessment. Neurology 1996; 46: 632-5
5. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematodes. Arch Neurol 1989; 46: 1121-3
6. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis. Washington, DC: Paralyzed Veterans of America, 1998
7. Mathiowetz V. Test-retest reliability and convergent validity of the Fatigue Impact Scale for persons with multiple sclerosis. Am J Occup Ther 2003 Jul-Aug; 57 (4): 389-95
8. Iriarte J. Katsamakis G. de Castro P. The Fatigue Descriptive Scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis. Multiple Sclerosis 1999 Feb; 5 (1): 10-6
9. Bloch KE, Schoch OD, Zhang JN, et al. German version of the Epworth Sleepiness Scale. Respiration 2000; 66: 440-7
10. Bakshi R, Shaikh ZA, Miletich RS, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 2000; 6: 181-5
11. Zivadinov R, Zorzon M, Bosco A, et al. Sexual dysfunction in multiple sclerosis, II: correlation analysis. Mult Scler 1999; 5: 428-31
12. Dickinson CJ. Chronic fatigue syndrome: aetiological aspects. Eur J Clin Invest 1997; 27: 257-67
13. Schwartz RB, Garada BM, Komaroff AL. Detection of intracranial abnormalities in patients with chronic fatigue syndrome: comparison of MR imaging and SPECT. Am J Roentgenol 1994; 162: 935-41
14. Filippi M, Rocca MA, Colombo B, et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 2002; 15 (3): 559-67
15. Roelcke U, Kappos L, Lechner-Scott J, et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997; 48: 1566-71
16. Sheean GL, Murray NMF, Rothwell JC, et al. An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain 1997; 120: 299-315
17. Rice CL, Volmer TL, Bigland-Ritchie B. Neuromuscular responses of patients with multiple sclerosis. Muscle Nerve 1992; 15: 1123-32
18. Garland SJ, Lavoie BA, Brown WF. Motor control of the diaphragm in multiple sclerosis. Muscle Nerve 1996; 19: 654-6
19. Kesselbrenner L, Akselrod S, Ahiron A, et al. Is fatigue in patients with multiple sclerosis related to autonomic dysfunction? Clin Auton Res 2000; 10: 169-75
20. Sharma KR, Kent-Braun J, Mynhier MA, et al. Evidence of an abnormal intramuscular component of fatigue in multiple sclerosis. Muscle Nerve 1995; 18: 1403-11
21. Zimmermann C, Hohlfeld R. Fatigue bei Multipler Sklerose. Nervenarzt 1999; 70: 566-74
22. Modafinil for the treatment of pathological somnolence in narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 1998; 43: 88-97
23. Damian MS, Gerlach A, Schmidt F, et al. Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology 2001; 56: 794-6
24. Happe S, Pirker W, Sauter C, et al. Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil. J Neurol 2001; 248: 632-4
25. Pack AI, Black JE, Schwartz JRL, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164: 1675-81
26. Kroencke D, Lynch SG, Denney DR. Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern. Mult Scler 2000; 6: 131-6
27. Hughes RJ, van Dongen H, Dinges DF, et al. Modafinil improve alertness an performance during simulated night work [abstract no. 336E]. Sleep 2002; 24: A200
28. Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002; 72: 179-83
29. Zifko UA, Rupp M. Erfolgreiche Behandlung der Tagesmüdigkeit bei multipler Sklerose mit Modafinil: ein Fallbericht [abstract]. Neuropsychiatry 2000; 14: 154
30. Zifko UA, Rupp M, Schwarz S, et al. Modafinil in treatment of fatigue in multiple sclerosis: results of an open-label study. J Neurol 2002; 249: 983-7
31. Terzoudi M, Gavrielidou P, Heilakos G, et al. Fatigue in multiple sclerosis: evaluation and a new pharmacological approach [abstract]. Neurology 2000; 54 Suppl. 3: A61
32. Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995; 45: 1956-61
33. Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989; 46: 676-80
34. Rosenberg GA, Appenzeller O. Amantadine, fatigue, and multiple sclerosis. Arch Neurol 1988; 14: 273-8
35. The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987; 14: 273-8
36. Braňas P, Jordan R, Fry-Smith A, et al. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000; 4 (27): 1-61
37. Taus C, Solari A, D'Amico R, et al. Amantadine for fatigue in multiple sclerosis (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2003
38. Weinshenker BG, Penman M, Bass B, et al. A double-blind, randomized, crossover trial of Pemolin in fatigue associated with multiple sclerosis. Neurology 1992; 42: 1468-71
39. Bever CT, Anderson PA, Leslie J, et al. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients. Neurology 1996; 47: 1457-62
40. Sheean GL, Murray NMF, Rothwell JC, et al. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 1998; 121: 867-975
41. vanDiemen HA, Polman CH, vanDongen MM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double blind, cross-over study. Ann Neurol 1991; 32: 123-30
42. Solari A, Uitdehaag B, Giuliani G, et al. Aminopyridines for symptomatic treatment in multiple sclerosis (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM], Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2003
43. Freeman JA, Thompson AJ. Inpatient rehabilitation in MS. Int Mult Scler J 1998; 5: 16-23
44. Freeman JA, Langdon DV, Hobart JC, et al. The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol 1997; 42: 236-44
45. Kidd D, Thompson AJ. A prospective study of neurorehabilitation in multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 62: 423-4
46. Solari A, Filippini G, Gasco P, et al. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 1999; 52: 57-62
47. Carey RG, Seibert JH. Who makes the most progress in inpatient rehabilitation?: an analysis of functional gain. Arch Phys Med Rehabil 1988; 9: 337-43
48. Petajan JH, Gappmaier E, White AT, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996; 39: 432-41
49. Richards TL, Lappin MS, Acosta-Urquidi J, et al. Double-blind study of pulsing magnetic field effects on multiple sclerosis [published erratum appears in J Altern Complement Med 1997; 3 (2): 205]. J Altern Complement Med 1997; 3: 21-9
50. Sandroni P, Walker C, Starr A. Fatigue in patients with multiple sclerosis: motor pathway conduction and event-related potentials. Arch Neurol 1992; 49: 517-24
51. Sandyk R. Treatment with weak electromagnetic fields improves fatigue associated with multiple sclerosis. Int J Neurosci 1996; 84: 177-86